Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qin-Qiao-Xiao-Du granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Beijing Institute of Traditional Chinese Medicine for the treatment of influenza. The name is derived from its primary constituent herbs, likely including *Scutellaria baicalensis* (Huang Qin) and *Forsythia suspensa* (Lian Qiao), which are traditionally recognized for their heat-clearing and detoxifying properties. The drug is administered orally as granules and has been evaluated in randomized controlled trials in China to assess its efficacy and safety compared to the standard antiviral oseltamivir in patients with confirmed influenza infections. Its mechanism of action is thought to involve a multi-target approach, combining direct antiviral activity with anti-inflammatory and immunomodulatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qin-qiao-xiao-du granules.